LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722.

Authors :: Mok, T.S.K.
Nakagawa, K.
Park, K.
Ohe, Y.
Girard, N.
Kim, H.R.
Wu, Y-L.
Gainor, J.
Lee, S-H.
Chiu, C-H.
Sang-We, K.
Cheng-Ta, Y.
Liang, W.
Wu, L.
Lin, M-C.
Samol, J.
Zhang, X.
Sylvester, J.
Li, S.
Yang, J.C-H.
Source :: Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1561-S1562. 2p.
Publication Year :: 2022

Subjects :: *NON-small-cell lung carcinoma
*PROTEIN-tyrosine kinase inhibitors
*NIVOLUMAB
*DISEASE progression
*EPIDERMAL growth factor receptors

Full Text Access

Tools